Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Asif Suria

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to close quickly. This explains why the spread on this Bristol Myers Squibb deal for Turning Point Therapeutics has a small spread of 1.89% or 5.85% annualized if the deal closes by the end of Q3 2022. Merger activity decreased last week with five new deals announced and two deals completed. One of the five new deals announced was a potential deal in the works.

Turning Point Therapeutics (NASDAQ:TPTX)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.